# IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
Canonical URL: https://biopharmsignal.com/news/INAB/in8bio-reports-first-quarter-2026-financial-results-and-recent-business-highlights
Ticker: INAB
Company: IN8bio
Source: IN8bio
Published: 2026-05-07 20:30 EST
Original Source URL: https://investors.in8bio.com
## Summary

Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026 Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs. standard-of-care; updated median overall survival (mOS) data to be presented at ASCO 2026 Hosting R&D Day on May

## Article Body
Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026 Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs. standard-of-care; updated median overall survival (mOS) data to be presented at ASCO 2026 Hosting R&D Day on May
## Recent Company News
- 2026-06-03 12:30 EST — [IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies](https://biopharmsignal.com/news/INAB/in8bio-announces-publication-in-nature-communications-highlighting-advances-in-gamma-delta-t-cell-engineering-and-combination-therapies) — Source: IN8bio
- 2026-06-01 12:30 EST — [IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026](https://biopharmsignal.com/news/INAB/in8bio-presents-updated-overall-survival-data-surpassing-19-5-months-for-deltex-dri-in-newly-diagnosed-glioblastoma-at-asco-2026) — Source: IN8bio
- 2026-05-14 12:00 EST — [IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma](https://biopharmsignal.com/news/INAB/in8bio-presents-new-translational-data-demonstrating-deltex-dri-reshapes-the-immune-landscape-in-glioblastoma) — Source: IN8bio
- 2026-05-07 20:30 EST — [IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/INAB/in8bio-reports-first-quarter-2026-financial-results-and-recent-business-highlights) — Source: IN8bio
- 2026-05-06 12:00 EST — [IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences](https://biopharmsignal.com/news/INAB/in8bio-to-showcase-next-generation-t-cell-engager-platform-and-new-clinical-data-at-upcoming-randd-day-and-medical-conferences) — Source: IN8bio
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)